Search

25 January 2021 A blood biomarker of tuberculosis discriminated between people at high risk for tuberculosis and those who remained healthy, but an effective preventive therapy for people at risk remains elusive.

26 Jan 2021 - 10:00

Researchers from the South African Tuberculosis Vaccine Initiative at the University of Cape Town, the Aurum Institute, the Centre for the AIDS Programme of Research in South Africa, Stellenbosch University, the London School of Hygiene and Tropical Medicine and the Fred Hutchinson Cancer Research Center have published the results from a study into a  blood-based RNA biomarker which tested diagnostic and prognostic performance for TB and the efficacy of TB preventive therapy for biomarker-positive individuals in The Lancet Infectious Diseases journal .

In the study a host blood signature of TB differentiated between people who had or would develop active TB and those who remained healthy, and investigated in parallel the effect of giving TB preventive therapy based on a positive signature result.

Click here to read media release.

Click here to read article online.